Home > National Drug Code (NDC) > Lamivudine and Zidovudine

Lamivudine and Zidovudine - 76519-1005-6 - (Lamivudine and Zidovudine)

Alphabetical Index


Drug Information of Lamivudine and Zidovudine

Product NDC: 76519-1005
Proprietary Name: Lamivudine and Zidovudine
Non Proprietary Name: Lamivudine and Zidovudine
Active Ingredient(s): 150; 300    mg/1; mg/1 & nbsp;   Lamivudine and Zidovudine
Administration Route(s): ORAL
Dosage Form(s): TABLET, FILM COATED
Coding System: National Drug Codes(NDC)

Labeler Information of Lamivudine and Zidovudine

Product NDC: 76519-1005
Labeler Name: H.J. Harkins Company, Inc.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: ANDA079081
Marketing Category: ANDA
Start Marketing Date: 20111227

Package Information of Lamivudine and Zidovudine

Package NDC: 76519-1005-6
Package Description: 6 TABLET, FILM COATED in 1 BOTTLE (76519-1005-6)

NDC Information of Lamivudine and Zidovudine

NDC Code 76519-1005-6
Proprietary Name Lamivudine and Zidovudine
Package Description 6 TABLET, FILM COATED in 1 BOTTLE (76519-1005-6)
Product NDC 76519-1005
Product Type Name HUMAN PRESCRIPTION DRUG
Non Proprietary Name Lamivudine and Zidovudine
Dosage Form Name TABLET, FILM COATED
Route Name ORAL
Start Marketing Date 20111227
Marketing Category Name ANDA
Labeler Name H.J. Harkins Company, Inc.
Substance Name LAMIVUDINE; ZIDOVUDINE
Strength Number 150; 300
Strength Unit mg/1; mg/1
Pharmaceutical Classes Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA]

Complete Information of Lamivudine and Zidovudine


General Information